Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 18Unknown 3Withdrawn 1Terminated 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Carcinoma, Hepatocellular 6Leukemia, Myeloid, Acute 4Thyroid Neoplasms 2Neoplasms 2Hepatoblastoma 2Thyroid cancer, Hurthle cell 1Thyroid Diseases 1Squamous Cell Carcinoma of Head and Neck 1Rhabdomyosarcoma 1Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroblastoma 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Melanoma 1Gastrointestinal Stromal Tumors 1Fibrolamellar hepatocellular carcinoma 1Desmoplastic Small Round Cell Tumor 1Carcinoma 1

Interventions

pembrolizumab 62Nivolumab 40Ipilimumab 24trametinib 13dabrafenib 10Specimen Handling 10Magnetic Resonance Spectroscopy 10binimetinib 9Cyclophosphamide 8CTLA-4 Antigen 8Biopsy 8encorafenib 7fludarabine 6Radiosurgery 6Cisplatin 6relatlimab 5cemiplimab 5atezolizumab 5Pemetrexed 5Introns 5Interleukin-2 5tislelizumab 4lenvatinib 4fludarabine phosphate 4durvalumab 4dostarlimab 4cobimetinib 4avelumab 4Radiotherapy 4Paclitaxel 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Melanoma × Sorafenib × Clear all
NCT01303341 2026-04-13

Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma

National Cancer Institute (NCI)

Phase 1 Active not recruiting
35 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡